Literature DB >> 7010875

Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA.

J Andersen, E Aabro, N Gulmann, A Hjelmsted, H E Pedersen.   

Abstract

Nineteen patients with L-DOPA treated parkinsonism involving depressive symptoms, the therapeutic effect of nortriptyline was compared to placebo in a controlled trial. The depressive and neurological symptoms were evaluated by rating scales. Nortriptyline had a clinical significant effect with regard to the depressive symptoms, whereas the neurological parameters were unchanged. The authors suggest the depression in Parkinson's disease to be of both reactive and endogenous origins.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7010875     DOI: 10.1111/j.1600-0404.1980.tb03028.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  28 in total

Review 1.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  D Aarsland; K Karlsen
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

3.  Specificity of affective and autonomic symptoms of depression in Parkinson's disease.

Authors:  S E Starkstein; T J Preziosi; A W Forrester; R G Robinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

4.  Depression rating scales in Parkinson's disease: critique and recommendations.

Authors:  Anette Schrag; Paolo Barone; Richard G Brown; Albert F G Leentjens; William M McDonald; Sergio Starkstein; Daniel Weintraub; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

Review 5.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

6.  Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.

Authors:  D Weintraub; S Mavandadi; E Mamikonyan; A D Siderowf; J E Duda; H I Hurtig; A Colcher; S S Horn; S Nazem; T R Ten Have; M B Stern
Journal:  Neurology       Date:  2010-08-03       Impact factor: 9.910

Review 7.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 8.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 9.  [Antidepressants for treatment of depression in palliative patients : a systematic literature review].

Authors:  M Ujeyl; B Müller-Oerlinghausen
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

Review 10.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.